Rxwire
Trials & R&D · first seen 52m ago, updated 52m ago

Alzheimer’s Drug Effects Revealed with Plasma Biomarker Changes

A longitudinal study of patients receiving lecanemab shows that Alzheimer’s treatment produces distinct molecular signatures in the blood. Importantly, the proteins linked to amyloid removal were largely different from those associated with…

Summary from Inside Precision Medicine.

Coverage 1 article · 1 outlet

  1. Inside Precision Medicine
    Alzheimer’s Drug Effects Revealed with Plasma Biomarker Changes